IDH1 and central nervous system cancer: Such in vivo MRS methods have also been shown to detect IDH mutations (Figures 1A, B) that were missed in IHC analyses, and the reduction in D-2HG levels has been used to monitor treatment response in patients with IDH-mutant gliomas and correlated with clinical status (82, 83).